Gene Engineering Division >  Depositors List > 

Ryohei Katayama's Resource

Ryohei Katayama's web page in English /  in Japanese.

Learn more about their research, in English  /  in Japanese (by Reseachmap[link])

Catalog #Name of cloneRunning titlePublication
RDB15488pENTER-EGFR wild-typeGateway(R) entry vector of human epidermal growth factor receptor (EGFR), wild type.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15489pENTER-EGFR Del19Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15490pENTER-EGFR T790M/del19Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15491pENTER-EGFR C797S/del19Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15492pENTER-EGFR C797S/T790M/del19Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15493pENTER-EGFR L858RGateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15494pENTER-EGFR T790M/L858RGateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15495pENTER-EGFR C797S/L858RGateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).
RDB15496pENTER-EGFR C797S/T790M/L858RGateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. (original).

go to top

2023.05.01

depxxxx_html_4_211208.pl